Shots:
- Insilico Medicine has entered into multiple AI-powered drug discovery collaborations with CMS, focusing on advancing therapeutic programs across CNS & autoimmune disease indications
- As per the deal, Insilico will leverage its Pharma.AI platform for target discovery & small-molecule design & optimization, while CMS will lead clinical development, regulatory strategy, trials, & commercialization
- Under the collaboration, Insilico & CMS will jointly advance the co-development of ≥2 research programs, with Insilico eligible for R&D funding of up to several tens of millions of HKD per program
Ref: PRnewswire  |  Image: Insilico & CMS  | Press Release
Related News: Insilico Medicine and Hygtia Therapeutics Partner to Advance ISM8969 for CNS Disorders
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
